As of November 6, 2026, Cerenome, Inc. is a publicly traded company (Nasdaq: CNSY); its largest reported holder is Highbridge, with 7.1% on Schedule 13G of May 15, 2026. The largest insider holding is Robert P. Lenk, a director, with 139,327 shares (1.8% of shares outstanding), per Form 4 of August 25, 2025. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13G, May 15, 2026).
Is this your company?
About to sign with, pay or invest in Cerenome, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Cerenome, Inc. a real, registered company?
- Plus Therapeutics, Inc. files with the SEC under CIK 1095981 (its SEC filings).
- Its shares are listed under the ticker CNSY on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Houston, Texas, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under CERENOME, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Highbridge (filed 2026-05-15).
Who are Cerenome, Inc.'s owners and officers?
Cerenome, Inc.: incorporated in Delaware; business address in Houston, Texas; industry Surgical & Medical Instruments & Apparatus (Form D, 2026-09-18).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-09-18)
- : Executive Officer (Form D, 2026-09-18)
- : Director (Form D, 2026-09-18)
- : Director (Form D, 2026-09-18)
- : Director (Form D, 2026-09-18)
- : Director (Form D, 2026-09-18)
- : Director (Form D, 2026-09-18)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-05-15 | Highbridge Capital Management, LLC | 7.1% |
| Schedule 13G/A, 2026-05-15 | Cvi Investments, Inc. | 4.9% |
| Schedule 13G, 2026-01-22 | Cvi Investments, Inc. | 6.9% |
| Schedule 13G/A, 2025-08-14 | S.H.N. Financial Investments LTD. | 1.51% |
| Schedule 13G/A, 2025-07-29 | Orin Hirschman | 3.9% |
Questions about who owns Cerenome, Inc.
Who owns Cerenome, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Cerenome, Inc.: Highbridge Capital Management, LLC (7.1%, Schedule 13G, filed 2026-05-15).
When did Highbridge Capital Management, LLC buy into Cerenome, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Highbridge Capital Management, LLC on this page is the Schedule 13G, filed 2026-05-15, reporting 7.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Cerenome, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cerenome, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cerenome, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Cerenome, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 139,327 shares (1.8% of shares outstanding) (Form 4, 2025-08-25).
- , the chief executive and a director: 60,922 shares (0.80% of shares outstanding) (Form 4, 2026-10-01).
- , the chief financial officer: 12,926 shares (0.17% of shares outstanding) (Form 4, 2026-10-01).
- , a director: 2,902 shares (0.04% of shares outstanding) (Form 4, 2026-10-01).
- , a director: 2,450 shares (0.03% of shares outstanding) (Form 4, 2026-10-01).
Shares outstanding: 7,589,625 as of 2026-08-05, from the company's latest SEC cover page.
How much has Cerenome, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-09-18 | $3M | $20M |
Latest IPO step: Cerenome, Inc. withdrew its IPO registration (RW, 2026-03-06).
IPO filings: RW, 2026-03-06, 424B4, 2026-01-14, S-1, 2026-01-09, S-1, 2025-08-12, RW, 2025-07-25.
Keep reading
More on Cerenome, Inc. and the records around it.
Cerenome, Inc. elsewhere on the record
- Form D filing Sep 2026
Companies that share a holder
- S.H.N. Financial Investments Ltd. also filed stake reports on 19 other companies: PRF Technologies Ltd. (Nov 2026), INLIF Ltd (Oct 2026), DarkIris Inc. (Oct 2026)
- Orin Hirschman also filed stake reports on 46 other companies: ASPEN AEROGELS, INC. (Oct 2026), Bionano Genomics, Inc. (Oct 2026), FENNEC PHARMACEUTICALS INC. (Oct 2026)
- CVI Investments, Inc. also filed stake reports on 48 other companies: Pine Tree Acquisition Corp. (Oct 2026), Sunshine Biopharma Inc. (Oct 2026), Outlook Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/plus-therapeutics